Amgen's Conundrum

Amgen is in a bit of a conundrum.

The big biotech's talimogene laherparepvec -- T-VEC for short -- passed its primary endpoint, lowering the durable response rate in melanoma patients. But a secondary endpoint of overall survival just missed being statistically significant, with a p-value of 0.051. The Food and Drug Administration typically likes to see a p-value of less than 0.05, which equates to less than a 5% chance that the observed difference was due to chance alone.

In the following video, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss Amgen's chances for success, whether it will be able to compete with Bristol-Myers Squibb's Yervoy, and its potential to be used in combination with Yervoy and Merck's anti-PD-1 antibody MK-3475.

No conundrum here, these industries should have megagrowth
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

The article Amgen's Conundrum originally appeared on

Brian OrelliMax Macaluso, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story